Cat. No. 1347
Chemical Name: N-[(1-Butyl-2-pyrrolidinyl)methyl]-
Biological ActivityHighly potent, competitive, preferential dopamine D3 receptor antagonist. Ki values are 0.52, 5, and 269 nM for human cloned D3, D2 and D4 receptors respectively. Centrally active upon systemic administration.
Licensing InformationSold with the permission of INSERM and BIOPROJET
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Richtand et al (2000) The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 867 239. PMID: 10837819.
Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187. PMID: 9765337.
Sautel et al (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J.Pharmacol.Exp.Ther. 275 1239. PMID: 8531087.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Nafadotride include:
Brewer et al (2014) Dopamine D3 receptor dysfunction prevents anti-nociceptive effects of morphine in the spinal cord. Front Neural Circuits 8 62. PMID: 24966815.
Clemens and Hochman (2004) Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 11337. PMID: 15601940.
Do you know of a great paper that uses Nafadotride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Nafadotride, supplier, potent, preferential, D3, antagonists, Dopamine, Receptors, dopaminergic, Tocris Bioscience, D3 Receptor Antagonist products